Key result
Novel and emerging lipid-lowering therapies achieve ~55% LDL-C reductions to target residual cardiovascular risk.
Why the study?
Statin intolerance and failure to achieve guideline LDL-C targets limit the utility of statins in managing dyslipidemia, necessitating review of current and emerging therapies.
A stepwise algorithm utilizing current and emerging antihyperlipidemic agents, including RNA-based and gene editing therapies, can optimize outcomes for patients with dyslipidemia and statin intolerance.
Dyslipidemia is a primary driver of atherosclerotic cardiovascular disease. While statins reduce LDL-C and cardiovascular events, statin intolerance and failure to achieve guideline targets limit their utility. To review the mechanism, efficacy, safety, and clinical positioning of current and emerging antihyperlipidemic agents as of May 2026. High-intensity statins remain first-line with 50-60% LDL-C reduction. Ezetimibe and bempedoic acid provide incremental LDL-C lowering of 15-28% without muscle toxicity. PCSK9 inhibitors and inclisiran achieve 50-60% reduction via distinct mechanisms, with inclisiran offering twice-yearly dosing. Bempedoic acid and inclisiran demonstrated cardiovascular outcome benefit in statin-intolerant populations. Gene editing therapy VERVE-101 showed single-dose LDL-C reductions of 39-55% in early trials. Therapeutic options now address statin intolerance, adherence barriers, and residual risk. A stepwise algorithm starting with oral agents and escalating to RNA-based therapies optimizes outcomes and resource use.
No takes yet. Share an insight, caveat, or question.
1Sudhanshu Tripathi, 2Pinky Baghel, 3*Dr. Anuj Mittal (2026) conducted a review in Dyslipidemia. Antihyperlipidemic agents was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: